Key result
Iodixanol reduces contrast-induced nephropathy ~59% vs. ioxaglate in renal impairment.
Why the study?
Does iodixanol reduce the incidence of contrast-induced nephropathy compared to ioxaglate in adults with renal impairment undergoing coronary angiography?
RCT (n=300)
randomized
Does iodixanol reduce the incidence of contrast-induced nephropathy compared to ioxaglate in adults with renal impairment undergoing coronary angiography?
Answers are grounded in this paper and cite their sources.
In patients with renal impairment undergoing coronary angiography, the iso-osmolar contrast medium iodixanol significantly reduces the risk of contrast-induced nephropathy compared to the low-osmolar contrast medium ioxaglate.
OBJECTIVES: This study sought to compare the nephrotoxicity of iodixanol and ioxaglate in patients with renal impairment undergoing coronary angiography. BACKGROUND: Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium (IOCM), may be less nephrotoxic than low-osmolar contrast media (LOCM) in high-risk patients. METHODS: In a prospective, randomized trial in 300 adults with creatinine clearance (CrCl) < or =60 ml/min, patients received either iodixanol or ioxaglate and underwent coronary angiography with or without percutaneous coronary intervention. The primary end point was the incidence of contrast-induced nephropathy (CIN) (an increase in serum creatinine [SCr] > or =25% or > or =0.5 mg/dl [> or =44.2 mumol/l]). The incidence of CIN in patients with severe renal impairment at baseline (CrCl <30 ml/min) or diabetes and in those receiving large doses (> or =140 ml) of contrast medium was also determined. RESULTS: The incidence of CIN was significantly lower with iodixanol (7.9%) than with ioxaglate (17.0%; p = 0.021), corresponding to an odds ratio (OR) of CIN of 0.415 (95% confidence interval [CI] 0.194 to 0.889) for iodixanol. The incidence of CIN was also significantly lower with iodixanol in patients with severe renal impairment (p = 0.023) or concomitant diabetes (p = 0.041), or in patients given > or =140 ml of contrast media (p = 0.038). Multivariate analysis identified use of ioxaglate (OR 2.65, 95% CI 1.11 to 6.33, p = 0.028), baseline SCr, mg/dl (OR 2.0, 95% CI 1.04 to 3.85, p = 0.038), and left ventricular ejection fraction, % (OR 0.97, 95% CI 0.94 to 0.99, p = 0.019) as independent risk factors for CIN. CONCLUSIONS: The IOCM iodixanol was significantly less nephrotoxic than ioxaglate, an ionic, dimeric LOCM. (The RECOVER Trial; http://clinicaltrials.gov; NCT00247325).
No takes yet. Share an insight, caveat, or question.
Jo et al. (2006) conducted an RCT in renal impairment undergoing coronary angiography (n=300). Iodixanol vs. Ioxaglate was evaluated on incidence of contrast-induced nephropathy (CIN) (an increase in serum creatinine [SCr] ≥25% or ≥0.5 mg/dl) (OR 0.415, 95% CI 0.194 to 0.889, p=0.021). Iodixanol reduced the incidence of contrast-induced nephropathy compared to ioxaglate in patients with renal impairment.
Synapse has enriched 10 related papers. Consider them for comparative context: